Nomura Takashi, Kawase Shinya, Watanabe Yasuhiro, Nakashima Kenji
Division of Neurology, Department of Brain and Neurosciences, Tottori University Faculty of Medicine, Japan.
Intern Med. 2013;52(18):2123-6. doi: 10.2169/internalmedicine.52.9179.
We used ramelteon to treat two patients with secondary REM sleep behavior disorder (RBD) complications along with neurodegenerative diseases including multiple system atrophy and Parkinson's disease. These two patients not only improved in terms of their clinical RBD symptoms but also exhibited a decrease in the proportion of REM sleep without atonia (from 8.5% to 3.5% and from 10.9% to 3.9% in the two patients). Although clonazepam is the standard first-line therapy for the treatment of RBD, ramelteon might be an effective treatment alternative in patients with RBD who cannot take clonazepam due to either ineffectiveness or adverse effects.
我们使用雷美替胺治疗了两名患有继发性快速眼动睡眠行为障碍（RBD）并发症以及包括多系统萎缩和帕金森病在内的神经退行性疾病的患者。这两名患者不仅临床RBD症状有所改善，而且快速眼动睡眠期无张力缺失的比例也有所下降（两名患者分别从8.5%降至3.5%，从10.9%降至3.9%）。尽管氯硝西泮是治疗RBD的标准一线疗法，但对于因无效或不良反应而无法服用氯硝西泮的RBD患者，雷美替胺可能是一种有效的替代治疗方法。
